Drug combination can slow lung cancer

A Japanese study has found that a drug combination rejected as a cancer treatment in the United States can add years to the lives of people with early lung cancer.

Lung cancer is one of the most common and lethal types of cancer, killing 85% of its sufferers. Only one other drug, cisplatin, has been shown to improve survival in early stages, and it adds only months.